
Medline Inc (MDLN) Stock Forecast & Price Target
Medline Inc (MDLN) Analyst Ratings
Bulls say
Medline's sales revenue demonstrated robust growth, increasing 11.47% year-over-year from $25.51 billion to $28.43 billion for the 12 months ending December 2025, underscoring the company's strong market position and demand for its offerings. The return on capital has also shown positive momentum, rising from 7.22% to 7.44%, which reflects effective capital utilization and significant economic profit potential. Additionally, Medline's brand now represents nearly half of its revenue and over 80% of its segment, with noteworthy performance in Surgical Solutions, indicating a solid foundation for continued growth and profitability through enhanced unit economics and expanded distribution capabilities.
Bears say
Medline's economic profit saw a significant decline of 220.79% year-over-year, shifting from a gain of $345.1 million to a loss of $416.9 million, primarily attributed to the cost measurement following its IPO. Additionally, Net Operating Profit After Tax (NOPAT) fell by 12.66% year-over-year, from $2.45 billion to $2.14 billion, indicating pressure on profitability amid challenging market conditions. The company also faced a 4.48% decline in Economic Operating Cash Flow (EBITDAR), from $3.71 billion to $3.54 billion, compounded by low-margin operating environments and potential risks associated with maintaining Prime Vendor relationships and competition.
This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.
Medline Inc (MDLN) Analyst Forecast & Price Prediction
Start investing in Medline Inc (MDLN)
Order type
Buy in
Order amount
Est. shares
0 shares